LDS/Medical Tests/Haptoglobin Genotyping

Haptoglobin Genotyping

Haptoglobin is a plasma glycoprotein produced in the liver. It has the capacity to bind free hemoglobin released into the circulation, thus preventing iron loss and renal damage during hemolysis or red blood cell destruction. When the hemoglobin-binding capacity of haptoglobin is exceeded, or concentrations of released free hemoglobin exceed available haptoglobin, plasma free hemoglobin is present and hemoglobinuria results. Haptoglobin also acts as an antioxidant, has antibacterial activity, and plays a role in modulating many aspects of the acute phase response. It is one of the acute phase proteins and is elevated in inflamatory conditions.  Haptoglobin polymorphisms have been associated with prevalence of infections, autoimmune diseases, and cardiovascular disease.

The haptoglobin gene is located on chromosome 16q22.1. Genetic variances have an autosomal inheritance pattern. Two co-dominant haptoglobin alleles, Hp1 and Hp2, result in three common haptoglobin phenotypes: HP-1, HP2-1, HP2-2. Individuals possessing these phenotypes produce a dysfunctional haptoglobin protein leading to an increase in inflammation and reduction of the reverse cholesterol transport of HDL.

Diabetics displaying the HP2-2 geneotype have a five-fold increased cardiovascular disease risk compared to patients with HP-1 genotype. Diabetic patients with confirmed HP2-2 genotyping may benefit from vitamin E treatment.

Possession of a particular phenotype has been associated with a variety of common disorders (e.g. cardiovascular disease, autoimmune disorders, malignancy), a fact which can only be explained by the idea that possession of a particular phenotype offers some protection against the development of these disorders. Knowledge of a patient’s phenotype could aid in the prognosis of disease and allow treatment to be better tailored to suit the individuals' needs. Haptoglobin testing along with an RBC count, Hgb (hemoglobin), and Hct (hematocrit) are critical in diagnosing hemolytic anemia.

  • Assessment of risk for coronary artery disease in diabetic patients
  • As an aid in diagnosis of blood hemolysis (severe and mild hemolysis)
  • Assessment of risk for adverse reaction during blood transfusion for patients who are genetically deficient in haptoglobin and also carry the anti-haptoglobin antibody
  • As an aid in diagnosis of ineffective erythropoiesis (megaloblastic anemias, hemoglobinopathies)
  • As an aid in diagnosis of hematomas and soft tissue hemorrhage which are associated with a decrease in haptoglobin

Hp2-2: phenotype consisting of Hp2 serum polymers of various sizes. Associated with increased risk of cardiovascular disease in diabetic patients.

Hp2-1: phenotype consisting of both Hp1 serum dimers and Hp2 polymers. Associated with intermediate risk for cardiovascular complications in diabetic patients.

Hp1-1: phenotype consisting of only Hp1 serum dimers. Lowest risk phenotype for cardiovascular complications in diabetic patients.

Depending on cause for lack of gene expression, Hp 1-1 genotype are at lowest risk for cardiovascular complications, ahaptoglobinemia (Hp0-0) or hypoheptoglobinemia (Hp1-0 or Hp2-0), are at risk of being misclassified.

 

 

Polymerase chain reaction (PCR), real time PCR, PCR / fluorescence monitoring, isoelectric focusing, chromatography, ELISA, LAMP (loop mediated isothermal amplification), PCR with restriction enzyme analysis, PCR with allele specific primer extension (ARMS).

Whole blood collected in lavender to tube (EDTA or ACD).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
Genetic counseling, haptoglobin level, HbA1c, triglyceride concentrations, C Reactive Protein, Alpha1 Acid Glycoprotein, Hemoglobin, Myoglobin.

3-7 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Perinat Med. 2000;28:249. [PMID: 11031696]
  • Clin Lab. 2000;46(11-12):547-52. [PMID: 11109501]
  • Am J Clin Pathol. 2004 Jun;121 Suppl:S97-104. [PMID: 15298155]
  • Clinical Chemistry. 2008;54(11): 1908-1913. [PMID: 18787013]
  • Clinical Chemistry. 2002; 48(9): 1377-1382. [PMID: 12194911]
  • Cardiovascular Diabetology. 2013;12(31). [PMID: 23399657]
  • Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login